Cecilia Veraar, Gudrun Lamm, Maximilian Will, Matthias Hammerer, Matthias Granner, Lion Merl, Konstantin Schwarz, Julia Mascherbauer
{"title":"Pacemaker Status and 5-Year Mortality After TAVI: A Sex-Specific Analysis","authors":"Cecilia Veraar, Gudrun Lamm, Maximilian Will, Matthias Hammerer, Matthias Granner, Lion Merl, Konstantin Schwarz, Julia Mascherbauer","doi":"10.1111/eci.70242","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Sex-specific differences regarding the prognostic impact of permanent pacemaker (PM) implantation after transcatheter aortic valve implantation (TAVI) remain largely unexplored.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To investigate sex-specific associations between pre-existing and new post-procedural PM implantation and short- and long-term mortality after TAVI.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This post hoc analysis of a prospective registry included consecutive patients who underwent TAVI between 2016 and 2020. Patients were stratified by sex and assigned to three groups: no PM, pre-existing PM (pre-PM) and PM implantation within 30 days of TAVI (post-PM). The primary endpoint was 5-year all-cause mortality; the secondary endpoint was 30-day mortality. Sex-stratified multivariable proportional hazards models and Kaplan–Meier analyses were performed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 1114 patients (81 ± 5 years, 49.8% female), women more frequently had no PM (80.2% vs. 70.8%, <i>p</i> < 0.001) and less often had a pre-existing PM (7.0% vs. 14.5%, <i>p</i> < 0.001). Post-PM rates were similar between sexes (12.8% vs. 14.7%, <i>p</i> = 0.172). Thirty-day survival differed by PM status only in women, with worse outcomes in the post-PM group (log-rank <i>p</i> = 0.033), whereas no difference was observed in men (<i>p</i> = 0.542). Five-year survival did not differ by PM status among women (<i>p</i> = 0.572) but differed significantly among men (<i>p</i> < 0.001), with the lowest survival in men with pre-PM.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Post-procedural PM implantation was associated with higher 30-day mortality in women, whereas pre-existing PM predicted reduced 5-year survival in men, supporting sex-specific risk assessment before and after TAVI.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 7","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70242","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.70242","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Sex-specific differences regarding the prognostic impact of permanent pacemaker (PM) implantation after transcatheter aortic valve implantation (TAVI) remain largely unexplored.
Objectives
To investigate sex-specific associations between pre-existing and new post-procedural PM implantation and short- and long-term mortality after TAVI.
Methods
This post hoc analysis of a prospective registry included consecutive patients who underwent TAVI between 2016 and 2020. Patients were stratified by sex and assigned to three groups: no PM, pre-existing PM (pre-PM) and PM implantation within 30 days of TAVI (post-PM). The primary endpoint was 5-year all-cause mortality; the secondary endpoint was 30-day mortality. Sex-stratified multivariable proportional hazards models and Kaplan–Meier analyses were performed.
Results
Among 1114 patients (81 ± 5 years, 49.8% female), women more frequently had no PM (80.2% vs. 70.8%, p < 0.001) and less often had a pre-existing PM (7.0% vs. 14.5%, p < 0.001). Post-PM rates were similar between sexes (12.8% vs. 14.7%, p = 0.172). Thirty-day survival differed by PM status only in women, with worse outcomes in the post-PM group (log-rank p = 0.033), whereas no difference was observed in men (p = 0.542). Five-year survival did not differ by PM status among women (p = 0.572) but differed significantly among men (p < 0.001), with the lowest survival in men with pre-PM.
Conclusion
Post-procedural PM implantation was associated with higher 30-day mortality in women, whereas pre-existing PM predicted reduced 5-year survival in men, supporting sex-specific risk assessment before and after TAVI.
背景:经导管主动脉瓣植入术(TAVI)后永久性起搏器(PM)植入术对预后影响的性别差异在很大程度上尚未研究。目的:研究TAVI术后已存在和新的PM植入与短期和长期死亡率之间的性别特异性关联。方法:这项前瞻性登记的事后分析包括2016年至2020年期间接受TAVI的连续患者。患者按性别分层,分为三组:无PM,已存在PM (PM前)和TAVI后30天内PM植入(PM后)。主要终点是5年全因死亡率;次要终点为30天死亡率。进行了性别分层的多变量比例风险模型和Kaplan-Meier分析。结果:在1114例患者(81±5岁,49.8%为女性)中,女性更经常没有PM (80.2% vs. 70.8%)。结论:手术后PM植入与女性较高的30天死亡率相关,而先前存在的PM预测男性5年生存率降低,支持TAVI前后性别特异性风险评估。
期刊介绍:
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.